PubMed:23633926 JSONTXT

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"23633926-1#34#38#gene1956","span":{"begin":127,"end":131},"obj":"gene1956"},{"id":"23633926-1#0#32#gene1956","span":{"begin":93,"end":125},"obj":"gene1956"},{"id":"23633926-1#34#38#gene1956","span":{"begin":127,"end":131},"obj":"gene1956"},{"id":"23633926-1#103#120#diseaseC0235974","span":{"begin":196,"end":213},"obj":"diseaseC0235974"},{"id":"23633926-1#103#120#diseaseC0346647","span":{"begin":196,"end":213},"obj":"diseaseC0346647"},{"id":"23633926-1#155#181#diseaseC0007131","span":{"begin":248,"end":274},"obj":"diseaseC0007131"}],"relations":[{"id":"34#38#gene1956103#120#diseaseC0235974","pred":"associated_with","subj":"23633926-1#34#38#gene1956","obj":"23633926-1#103#120#diseaseC0235974"},{"id":"34#38#gene1956103#120#diseaseC0346647","pred":"associated_with","subj":"23633926-1#34#38#gene1956","obj":"23633926-1#103#120#diseaseC0346647"},{"id":"34#38#gene1956155#181#diseaseC0007131","pred":"associated_with","subj":"23633926-1#34#38#gene1956","obj":"23633926-1#155#181#diseaseC0007131"},{"id":"0#32#gene1956103#120#diseaseC0235974","pred":"associated_with","subj":"23633926-1#0#32#gene1956","obj":"23633926-1#103#120#diseaseC0235974"},{"id":"0#32#gene1956103#120#diseaseC0346647","pred":"associated_with","subj":"23633926-1#0#32#gene1956","obj":"23633926-1#103#120#diseaseC0346647"},{"id":"0#32#gene1956155#181#diseaseC0007131","pred":"associated_with","subj":"23633926-1#0#32#gene1956","obj":"23633926-1#155#181#diseaseC0007131"},{"id":"34#38#gene1956103#120#diseaseC0235974","pred":"associated_with","subj":"23633926-1#34#38#gene1956","obj":"23633926-1#103#120#diseaseC0235974"},{"id":"34#38#gene1956103#120#diseaseC0346647","pred":"associated_with","subj":"23633926-1#34#38#gene1956","obj":"23633926-1#103#120#diseaseC0346647"},{"id":"34#38#gene1956155#181#diseaseC0007131","pred":"associated_with","subj":"23633926-1#34#38#gene1956","obj":"23633926-1#155#181#diseaseC0007131"}],"text":"Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.\nEpidermal growth factor receptor (EGFR) is overexpressed in a variety of human malignancies, including pancreatic cancer, breast cancer, colon cancer, and non-small cell lung cancer. Overexpression of EGFR is a predictive marker of therapeutic response and several lines of evidence suggest that EGFR is an excellent target for tumor therapy. However, the effective antitumor capacity of EGFR-specific T cells against EGFR-overexpressing tumor cells has not been fully elucidated. In our previous study, we identified an anti-EGFR single-chain variable fragment (scFv) with specific and high affinity after screening by ribosome display. In this study, the anticancer potential of anti-EGFR scFv was investigated on the basis of cell-targeted therapy. A chimeric antigen receptor (CAR) targeting EGFR was constructed and expressed on the cell membrane of T lymphocytes. These CAR-modified T cells demonstrated antitumor efficacy both in vitro and in vivo. In addition, the safety evaluation showed that CAR-modified lymphocytes have no or very minimal acute systemic toxicity. Taken together, our study provided the experimental basis for clinical application of genetically engineered lymphocytes; moreover, we also evaluate a new and interesting cell therapy protocol."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":64,"end":68},"obj":"gene:1956"},{"id":"T1","span":{"begin":27,"end":36},"obj":"disease:C0007097"},{"id":"T2","span":{"begin":127,"end":131},"obj":"gene:1956"},{"id":"T3","span":{"begin":196,"end":213},"obj":"disease:C0235974"},{"id":"T4","span":{"begin":127,"end":131},"obj":"gene:1956"},{"id":"T5","span":{"begin":172,"end":184},"obj":"disease:C0006826"},{"id":"T6","span":{"begin":93,"end":125},"obj":"gene:1956"},{"id":"T7","span":{"begin":248,"end":274},"obj":"disease:C0007131"},{"id":"T8","span":{"begin":127,"end":131},"obj":"gene:1956"},{"id":"T9","span":{"begin":196,"end":213},"obj":"disease:C0346647"},{"id":"T10","span":{"begin":127,"end":131},"obj":"gene:1956"},{"id":"T11","span":{"begin":248,"end":274},"obj":"disease:C0007131"},{"id":"T12","span":{"begin":93,"end":125},"obj":"gene:1956"},{"id":"T13","span":{"begin":172,"end":184},"obj":"disease:C0006826"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"},{"id":"R6","pred":"associated_with","subj":"T10","obj":"T11"},{"id":"R7","pred":"associated_with","subj":"T12","obj":"T13"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.\nEpidermal growth factor receptor (EGFR) is overexpressed in a variety of human malignancies, including pancreatic cancer, breast cancer, colon cancer, and non-small cell lung cancer. Overexpression of EGFR is a predictive marker of therapeutic response and several lines of evidence suggest that EGFR is an excellent target for tumor therapy. However, the effective antitumor capacity of EGFR-specific T cells against EGFR-overexpressing tumor cells has not been fully elucidated. In our previous study, we identified an anti-EGFR single-chain variable fragment (scFv) with specific and high affinity after screening by ribosome display. In this study, the anticancer potential of anti-EGFR scFv was investigated on the basis of cell-targeted therapy. A chimeric antigen receptor (CAR) targeting EGFR was constructed and expressed on the cell membrane of T lymphocytes. These CAR-modified T cells demonstrated antitumor efficacy both in vitro and in vivo. In addition, the safety evaluation showed that CAR-modified lymphocytes have no or very minimal acute systemic toxicity. Taken together, our study provided the experimental basis for clinical application of genetically engineered lymphocytes; moreover, we also evaluate a new and interesting cell therapy protocol."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":196,"end":213},"obj":"HP_0002894"},{"id":"T2","span":{"begin":207,"end":213},"obj":"HP_0002664"},{"id":"T3","span":{"begin":215,"end":228},"obj":"HP_0003002"},{"id":"T4","span":{"begin":215,"end":228},"obj":"HP_0100013"},{"id":"T5","span":{"begin":222,"end":228},"obj":"HP_0002664"},{"id":"T6","span":{"begin":230,"end":242},"obj":"HP_0003003"},{"id":"T7","span":{"begin":230,"end":242},"obj":"HP_0100273"},{"id":"T8","span":{"begin":236,"end":242},"obj":"HP_0002664"},{"id":"T9","span":{"begin":248,"end":274},"obj":"HP_0030358"},{"id":"T10","span":{"begin":252,"end":274},"obj":"HP_0030357"},{"id":"T11","span":{"begin":263,"end":274},"obj":"HP_0100526"},{"id":"T12","span":{"begin":268,"end":274},"obj":"HP_0002664"},{"id":"T13","span":{"begin":421,"end":426},"obj":"HP_0002664"},{"id":"T14","span":{"begin":531,"end":536},"obj":"HP_0002664"}],"text":"Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.\nEpidermal growth factor receptor (EGFR) is overexpressed in a variety of human malignancies, including pancreatic cancer, breast cancer, colon cancer, and non-small cell lung cancer. Overexpression of EGFR is a predictive marker of therapeutic response and several lines of evidence suggest that EGFR is an excellent target for tumor therapy. However, the effective antitumor capacity of EGFR-specific T cells against EGFR-overexpressing tumor cells has not been fully elucidated. In our previous study, we identified an anti-EGFR single-chain variable fragment (scFv) with specific and high affinity after screening by ribosome display. In this study, the anticancer potential of anti-EGFR scFv was investigated on the basis of cell-targeted therapy. A chimeric antigen receptor (CAR) targeting EGFR was constructed and expressed on the cell membrane of T lymphocytes. These CAR-modified T cells demonstrated antitumor efficacy both in vitro and in vivo. In addition, the safety evaluation showed that CAR-modified lymphocytes have no or very minimal acute systemic toxicity. Taken together, our study provided the experimental basis for clinical application of genetically engineered lymphocytes; moreover, we also evaluate a new and interesting cell therapy protocol."}

{"project":"Allie","denotations":[{"id":"SS1_23633926_1_0","span":{"begin":93,"end":125},"obj":"expanded"},{"id":"SS2_23633926_1_0","span":{"begin":127,"end":131},"obj":"abbr"},{"id":"SS1_23633926_4_0","span":{"begin":624,"end":654},"obj":"expanded"},{"id":"SS2_23633926_4_0","span":{"begin":656,"end":660},"obj":"abbr"},{"id":"SS1_23633926_6_0","span":{"begin":847,"end":872},"obj":"expanded"},{"id":"SS2_23633926_6_0","span":{"begin":874,"end":877},"obj":"abbr"}],"relations":[{"id":"AE1_23633926_1_0","pred":"abbreviatedTo","subj":"SS1_23633926_1_0","obj":"SS2_23633926_1_0"},{"id":"AE1_23633926_4_0","pred":"abbreviatedTo","subj":"SS1_23633926_4_0","obj":"SS2_23633926_4_0"},{"id":"AE1_23633926_6_0","pred":"abbreviatedTo","subj":"SS1_23633926_6_0","obj":"SS2_23633926_6_0"}],"text":"Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.\nEpidermal growth factor receptor (EGFR) is overexpressed in a variety of human malignancies, including pancreatic cancer, breast cancer, colon cancer, and non-small cell lung cancer. Overexpression of EGFR is a predictive marker of therapeutic response and several lines of evidence suggest that EGFR is an excellent target for tumor therapy. However, the effective antitumor capacity of EGFR-specific T cells against EGFR-overexpressing tumor cells has not been fully elucidated. In our previous study, we identified an anti-EGFR single-chain variable fragment (scFv) with specific and high affinity after screening by ribosome display. In this study, the anticancer potential of anti-EGFR scFv was investigated on the basis of cell-targeted therapy. A chimeric antigen receptor (CAR) targeting EGFR was constructed and expressed on the cell membrane of T lymphocytes. These CAR-modified T cells demonstrated antitumor efficacy both in vitro and in vivo. In addition, the safety evaluation showed that CAR-modified lymphocytes have no or very minimal acute systemic toxicity. Taken together, our study provided the experimental basis for clinical application of genetically engineered lymphocytes; moreover, we also evaluate a new and interesting cell therapy protocol."}